Adolescents who experience less sleep show a decreased willingness to engage in sports activities that require effort through fine motor coordination and attention to detail.Great sleep deprivation mimics psychosis: distorted perceptions can lead to inappropriate emotional and behavioral responses.Astronauts have reported performance errors and decreased cognitive ability during periods of extended working hours and wakefulness as well as due to sleep loss caused by circadian rhythm disruption and environmental factors.One study has found that a single night of sleep deprivation may cause tachycardia, a condition in which the heartrate exceeds 100 beats per minute (in the following day).Generally, sleep deprivation may facilitate or intensify:
aching muscles
confusion, memory lapses or loss
depression
development of false memory
hypnagogic and hypnopompic hallucinations during falling asleep and waking, which are entirely normal
hand tremor
headaches
malaise
stye
periorbital puffiness, commonly known as "bags under eyes" or eye bags
increased blood pressure
increased stress hormone levels
increased risk of Type 2 diabetes
lowering of immunity, increased susceptibility to illness
increased risk of fibromyalgia
irritability
nystagmus (rapid involuntary rhythmic eye movement)
obesity
seizures
temper tantrums in children
violent behavior
yawning
mania
Sleep inertia
symptoms similar to:
attention-deficit hyperactivity disorder (ADHD)
psychosis

Assessment
Patients with sleep deprivation may present with complaints of symptoms and signs of insufficient sleep such as fatigue, sleepiness, drowsy driving, and cognitive difficulties. Sleep insufficiency can easily go unrecognized and undiagnosed unless patients are specifically asked about it by their clinicians.Several questions are critical in evaluating sleep duration and quality, as well as the cause of sleep deprivation.
The applicant for this medicinal product is Merck Europe B.V. Tepotinib (Tepmetko) was approved for medical use in the European Union in February 2022. References
Further reading
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC,  et al. (September 2020). "Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations". N Engl J Med. 383 (10): 931–43. doi:10.1056/NEJMoa2004407. PMC 8422679. PMID 32469185. External links
"Tepotinib". Drug Information Portal. U.S. National Library of Medicine. "Tepotinib hydrochloride". Drug Information Portal. U.S. National Library of Medicine. "Tepotinib hydrochloride". NCI Drug Dictionary. National Cancer Institute. Clinical trial number NCT02864992 for "Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION)" at ClinicalTrials.gov